close Icon

Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma.

Hutchinson AT, Jones DR, Raison RL

  • Journal Molecular immunology

  • Published 08 May 2015

  • Volume 67

  • ISSUE 2 Pt A

  • Pagination 89-94

  • DOI 10.1016/j.molimm.2015.04.013


Monoclonal antibodies (mAb) have had tremendous success in treating a variety of cancers over the past twenty years. Yet despite their widespread clinical use, which includes treatments for haematological malignancies, there are still no approved mAb therapies for multiple myeloma (MM). This is likely to change within the next few years with a number of mAb therapies being assessed in late stage clinical trials, most notably, the anti-CS-1 mAb, elotuzumab, and the anti-CD38 mAb, daratumumab, which are currently being evaluated in Phase III clinical trials for MM. In this review, we will discuss the preclinical and clinical development of MDX-1097, a Phase II candidate which targets cell membrane-associated kappa immunoglobulin free light chains expressed on the surface of MM cells.